Skip to main navigation Skip to search Skip to main content

Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia

  • Sarah Cooley
  • , Daniel J. Weisdorf
  • , Lisbeth A. Guethlein
  • , John P. Klein
  • , Tao Wang
  • , Steven G.E. Marsh
  • , Stephen Spellman
  • , Michael D. Haagenson
  • , Koy Saeturn
  • , Martha Ladner
  • , Elizabeth Trachtenberg
  • , Peter Parham
  • , Jeffrey S. Miller

Research output: Contribution to journal › Article › peer-review

Abstract

Killer cell Ig-like receptors (KIRs) interact with HLA class I ligands to regulate NK cell development and function. These interactions affect the outcome of unrelated donor hematopoietic cell transplantation (HCT).We have shown previously that donors with KIR B versus KIR A haplotypes improve the clinical outcome for patients with acute myelogenous leukemia by reducing the incidence of leukemic relapse and improving leukemia-free survival (LFS). Both centromeric and telomeric KIR B genes contribute to the effect, but the centromeric genes are dominant. They include the genes encoding inhibitory KIRs that are specific for the C1 and C2 epitopes of HLA-C. We used an expanded cohort of 1532 T cell-replete transplants to examine the interaction between donor KIR B genes and recipient class I HLA KIR ligands. The relapse protection associated with donor KIR B is enhanced in recipients who have one or two C1-bearing HLA-C allotypes, compared with C2 homozygous recipients, with no effect due to donor HLA. The protective interaction between donors with two or more, versus none or one, KIR B motifs and recipient C1 was specific to transplants with class I mismatch at HLA-C (RR of leukemia-free survival, 0.57 [0.40-0.79]; p = 0.001) irrespective of the KIR ligand mismatch status of the transplant. The survival advantage and relapse protection in C1/x recipients compared with C2/C2 recipients was similar irrespective of the particular donor KIR B genes. Understanding the interactions between donor KIR and recipient HLA class I can be used to inform donor selection to improve outcome of unrelated donor hematopoietic cell transplantation for acute myelogenous leukemia.

Original languageEnglish (US)
Pages (from-to)4592-4600
Number of pages9
JournalJournal of Immunology
Volume192
Issue number10
DOIs
StatePublished - May 15 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia'. Together they form a unique fingerprint.

Cite this